UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 1, 2021
 
Acorda Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)

Delaware	001-31938	13-3831168		
(State or Other Jurisdiction
of Incorporation)	(Commission File Number)	(IRS Employer
Identification No.)		
 	 	 		
420 Saw Mill River Road,
Ardsley, NY	 	10502		
(Address of Principal Executive Offices)	 	(Zip Code)		
Registrant’s Telephone Number, Including Area Code: (914) 347-4300
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
 
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class	 	Trading
Symbol(s)	 	Name of each exchange on which registered	
Common Stock, $0.001 par value per share	 	ACOR	 	Nasdaq Global Select Market	
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
Item 8.01. Other Events.
 
On December 1, 2021, Acorda Therapeutics, Inc. (the “Company”) issued to the holders of its 6.00% Convertible Senior Secured Notes due 2024 (the “Notes”) an aggregate of 2,049,041 shares of the Company’s common stock (the “Shares”), in satisfaction of approximately $6.2 million in interest due under the Notes on such date. Pursuant to the indenture under which the Notes were issued, the Company may elect to pay interest in cash or shares of the Company’s common stock based on the formula set forth in the indenture. In connection with the issuance of the Shares, an amount corresponding to the $6.2 million of accrued interest will be released from escrow and will be available to the Company for other purposes. The issuance of the Shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	 	Description	
4.1	 	Indenture, dated as of December 23, 2019, among the Company, the guarantors party thereto, and Wilmington Trust, National Association, as trustee and collateral agent (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on December 26, 2019).	
4.2	 	Form of 6.00% Convertible Senior Secured Notes due 2024 (included in Exhibit 4.1)	
104	 	Cover Page Interactive Data File (embedded within the Inline XBRL document)	

 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	Acorda Therapeutics, Inc.	
 	 	 	
December 2, 2021	By:	/s/ Michael Gesser	
 	 	Name: Michael Gesser	
 	 	Title: Chief Financial Officer